Forem: Omnis Coder

Biotech companies NEED continuous IP monitoring

Omnis Coder — Fri, 09 Jan 2026 19:14:21 +0000

Bayer just sued Pfizer, Moderna, BioNTech, and J&J over alleged infringement of foundational mRNA vaccine technology — a fight that threatens to recast who owns the core building blocks of one of the biggest biotech success stories of our era.

Biogen was slapped with a $124 million royalty verdict for using a monoclonal antibody process it believed was safe, proving that even entrenched incumbents can misread the IP landscape at their peril.

Sequencing giants Illumina, 10x Genomics, and Element Biosciences are now locked in open patent wars over next-generation genomic platforms — high-stakes disputes over the very tools that drive modern biotech innovation.

With hundreds of patent lawsuits filed in the last two years alone, biotech is no longer a science-only business.

It’s a legal minefield where one overlooked claim can erase billions in enterprise value.

How Does This Happen?

Most biotech companies treat intellectual property like a static asset:

File patents
Track competitors once a year
Call outside counsel when something feels wrong

That model is already broken.

In modern biotech, IP risk is continuous. Your exposure changes every time:

A paper drops
A preprint lands
A patent publishes
A competitor tweaks a claim

If you are not monitoring that surface area continuously, you are flying blind while burning tens or hundreds of millions of dollars.

This is not hypothetical.

This is already happening.

Biotech IP Is No Longer Stable

Biotech IP used to move slowly.

Patent filings took years to surface
Scientific progress was gated by wet-lab timelines
Competitive overlap unfolded over decades

That world is gone.

Today:

Preprints precede patents
Platform technologies evolve monthly
Claim language shifts incrementally but strategically
AI-assisted patent drafting accelerates filing velocity
Genome editing methods converge rapidly across labs

Your freedom to operate can change without warning.

And it often does.

The Hidden Risk Nobody Tracks

Most companies monitor competitors at the company level.

That is not where the risk lives.

The risk lives in:

Claim language drift
Narrow amendments that still block execution
Method overlap across workflows
Dependency on upstream platform IP
Silent convergence on the same technical solution

By the time a lawsuit happens, the damage is already done.

Litigation is not a warning signal.

It is a post-mortem.

Annual IP Reviews Are Theater

Many biotech teams do an annual or quarterly IP review.

This feels responsible.

It is not.

A yearly snapshot in a field that moves weekly is worse than useless. It creates false confidence. Leadership believes risk is under control while engineers and scientists continue building on shifting ground.

IP risk is not a calendar event.

It is a stream.

Why Continuous Monitoring Changes the Game

Continuous IP monitoring flips the problem.

Instead of asking:

“Are we infringing?”

You ask:

“How is the IP landscape evolving relative to our roadmap?”

That difference matters.

With continuous monitoring you can:

Detect early claim encroachment
Quantify risk before product decisions lock in
Identify divergence opportunities before competitors see them
Adjust design choices while change is still cheap
Create documented evidence of diligence and intent

No legal paranoia.

This is operational discipline.

This Is Now a Board-Level Issue

If you are deploying capital into:

CRISPR or Prime Editing
Gene therapy platforms
Synthetic biology pipelines
AI-driven biology systems
Any programmable biological system

Then IP drift is existential.

A single blocking claim can invalidate years of work.

A single overlooked filing can freeze partnerships or derail acquisition talks.

Boards already expect:

Continuous security monitoring
Continuous compliance monitoring

They will soon expect continuous IP monitoring.

The companies that adopt it early will look disciplined.

The ones that do not will look reckless in hindsight.

The Hard Truth

If you are only checking IP when lawyers tell you to, you are already late.

If your scientists do not know how close they are to active claims, they are making decisions in the dark.

And if your IP posture cannot be replayed, audited, and defended over time, you do not actually control it.

Continuous IP monitoring is not optional anymore.

It is the cost of operating in modern biotech.

VeriBiota v0.2.1: Deterministic Verification with Proven Guarantees

Omnis Coder — Thu, 18 Dec 2025 15:02:50 +0000

This is the first release we’re comfortable calling product grade.
The goal is simple: trust that comes from alignment and verification, not from promises or marketing diagrams.
VeriBiota drops into existing computational biology pipelines without ceremony. You run it locally or in CI, it checks what you said you produced, and it tells you very clearly when something does not hold.

What it does in practice

• Runs locally or in CI
• Emits deterministic artifacts
• Fails loudly when invariants break
• Leaves a durable audit trail: schemas, hashes, provenance records, optional signing

What v0.2.1 actually delivers

Deterministic verification of structured biology artifacts. Profile checks return stable exit codes and machine readable verdicts that CI can gate on.

Reproducible provenance records

designed for audits and post mortems, not screenshots.

Formally proven guarantees for selected invariants, backed by Lean theorems, not placeholders.

Zero friction adoption.

Prebuilt binaries and a pinned container. No Lean install required to use it.

Proven today (Lean backed)

These profiles are not aspirational. They are backed by non placeholder Lean theorem anchors.
Global affine alignment correctness
global_affine_v1
Edit script application correctness
edit_script_v1
Edit script normalization
edit_script_normal_form_v1
Semantic preservation plus idempotence
Snapshot provenance binding
snapshot_signature_v1

Verification outputs are provably bound to

• the input hash
• the registered schema identity and schema hash
• the registered theorem list
Contract checked today (proofs expanding)
These profiles are enforced by schema aligned decoding, executable checks, fixtures, and CI. Formal proofs are planned and actively being added.
PairHMM bridge
pair_hmm_bridge_v1
Prime editing plans
prime_edit_plan_v1
VCF normalization
vcf_normalization_v1
Some profiles may appear in the manifest but are not yet routed through veribiota check. That is intentional and explicit.
A necessary clarification about snapshot signatures
snapshot_signature_v1 is not a cryptographic signature.
It is a provenance binding record. It guarantees integrity and traceability of verification outputs through canonical JSON and hash binding. It does not provide non repudiation.
If you need cryptographic authenticity, use the Ed25519 and JWS signing flow for checks and certificates, verified via JWKS. That system is separate by design.
Try it in CI
No Lean install. No setup gymnastics.
docker pull ghcr.io/omnisgenomics/veribiota:v0.2.1

mkdir -p ci_signatures

docker run --rm \ -v "$PWD":/work \ -w /work \ ghcr.io/omnisgenomics/veribiota:v0.2.1 \ check alignment global_affine_v1 \ examples/profiles/global_affine_v1/match.json \ --snapshot-out ci_signatures/global_affine_v1.sig.json \ --compact

This release is about setting a floor. Determinism, verification, provenance, and proofs where they matter. The surface area will grow, but the contract does not get softer.

Github
Docs

CRISPR Off-Target Prediction Was Never a Biology Problem

Omnis Coder — Wed, 17 Dec 2025 19:12:09 +0000

For years the story has been simple. CRISPR editing is powerful but risky because biology is messy. DNA folds. Chromatin hides sites. Cells repair breaks unpredictably. Therefore off target edits are an unavoidable biological tax.

That story is comforting. It lets us treat errors as fate.

It is also wrong.

Off target prediction was never primarily a biology problem. It is a computation problem that biology exposed.

The real constraint was always search

Take a step back. What is off target prediction in concrete terms?

You have a guide sequence. You have a genome that is billions of bases long. You want to find every location that is sufficiently similar to the guide under a mismatch and bulge model and then score each candidate by cleavage likelihood.

That is not biology. That is approximate string matching at scale.

For a long time we pretended this was solved. We aligned reads. We used heuristics. We pruned aggressively. We capped mismatches. We ignored bulges or treated them as an afterthought.

Why? Because exhaustive search was computationally impossible on commodity hardware. The genome is too large. The state space explodes.

So we called the misses biology.

Heuristics dressed up as insight

Most classic off target tools are a pile of shortcuts.

Seed and extend approaches that assume mismatches near the PAM dominate.

Hard cutoffs like no more than three mismatches.

Precomputed indices that quietly drop entire classes of candidates.

Scoring functions trained on partial data because generating full negative sets was too expensive.

These methods worked just well enough to publish and just poorly enough to leave labs nervous.

The uncomfortable truth is that we never actually evaluated most of the genome. We sampled it.

Biology did not fail us

When people say off target effects are unpredictable they are usually describing model blind spots.

We failed to enumerate all plausible binding sites.

We failed to propagate uncertainty through the repair process.

We failed to measure the long tail because the long tail was computationally expensive.

Cells did not become stochastic out of spite. We just did not look carefully enough.

The GPU changed the game

Everything changes when you can actually search.

Modern GPUs can evaluate billions of candidate alignments per second. They can score mismatch patterns exhaustively. They can simulate cleavage likelihood across full genomes without heuristic pruning.

Once you remove the artificial limits the supposed biological chaos starts to look structured.

Off target sites cluster.

Mismatch tolerance follows smooth gradients.

Repair outcomes obey conditional distributions.

None of this is mysterious if you can afford to compute it.

Prediction improves when you stop guessing

The best recent gains in off target prediction did not come from new wet lab tricks. They came from better enumeration and better models.

Full genome search rather than seed limited search.

Explicit bulge handling rather than ignoring indels.

Energy based or mechanistic scoring rather than black box thresholds.

The more complete the search the less magic biology appears to contain.

What this means for CRISPR platforms

If you are still treating off target prediction as an experimental art you are leaving performance on the table.

The path forward is clear.

Treat guide design as a systems problem.

Run exhaustive candidate generation.

Score with transparent models that expose uncertainty.

Simulate repair not as noise but as a conditional process.

This is not future science fiction. It is an engineering problem that finally fits inside modern compute budgets.

The uncomfortable conclusion

Biology did not betray us.

Our algorithms did.

For a decade we blamed cells for behavior that our software was too slow to predict. Now that compute has caught up the fog is lifting.

CRISPR off target prediction was never a biology problem. It was a search problem hiding inside biology.

And search problems eventually lose.

If you are building CRISPR tools today the question is no longer whether off target prediction can improve. It is whether you are willing to abandon comforting heuristics and actually compute the answer.

Building a CRISPR/Prime Editing Planner with Next.js + FastAPI

Omnis Coder — Mon, 24 Nov 2025 05:15:35 +0000

Designing CRISPR and Prime Editing experiments usually means jumping between half a dozen tools, copying sequences around, manually checking GC content, validating coordinates, and hoping you didn’t introduce an off-by-one error. It’s slow, tedious, and surprisingly easy to f*** up.

So, we built something better.

Helix Edit Planner

A fast, browser-based CRISPR/Prime Editing design tool powered by a Next.js frontend and a FastAPI backend:

Helix Edit Planner

Paste a sequence, describe the edit, and the planner generates

Candidate CRISPR guides
Prime Editing designs (PBS, RT templates)
GC content, distances, PAM positions
Clear ASCII-style diagrams
Sanity checks and flags

All computed in real time.

Why build a planner at all?

Even basic CRISPR edits require a surprising amount of bookkeeping
| “Does this guide bind at the right offset?”
| “Is the PAM in the right position relative to the edit?”
| “What is the GC balance?”
| “Is this pegRNA even viable given the direction and sizes?”
| “Did I miscount bases around the edit?”

Doing this manually is a trap.

We wanted a tool that made CRISPR design feel like writing code, fast feedback, clear structure, self-contained validation.

Tech Stack Overview

Frontend: Next.js on Vercel

Instant feedback as the user types
Clean form inputs for target sequence + edit specification
Generates ASCII diagrams for guide binding and edit sites
Handles client-side validation before hitting the backend

Backend: FastAPI on Fly.io

The backend does the actual sequence logic.
Endpoints include:
/api/crispr – find candidate guides
/api/prime – compute prime editing RT/PBS designs
/api/flags – attach warnings and metrics

FastAPI made it easy to keep the models clean and the responses strictly typed:

class CrisprGuide(BaseModel):
    sequence: str
    pam: str
    start: int
    end: int
    gc_content: float
    strand: Literal["+", "-"]

This structure alone removed half the bugs typical in ad-hoc CRISPR design tools.

How the system works (high level)

User Submits:

a target sequence
an edit specification (e.g., pos=123, ref=G, alt=A)
CRISPR or Prime Editing mode

the planner computes:

PAM scanning For example, in SpCas9 mode: NGG on the plus strand CCN on the minus strand

Each hit becomes a potential guide.

Motif extraction + GC content
A quick calculation:
gc = (seq.count("G") + seq.count("C")) / len(seq)
Helps detect unstable 20nt guides.
Edit-to-guide distance rules
Prime editing gets stricter:
Peg must extend toward the edit
RT must include the altered bases
PBS must be reverse-complemented

This is where most off-by-one errors normally hide, and where automation helps the most.

Diagram generation

We emit a small ASCII representation showing guide binding:

Users consistently say this is the most reassuring part.

Sample FastAPI snippet (Prime Editing core)

Here’s a simplified version of how we generate RT + PBS:

def build_prime_edit(seq, pos, ref, alt, guide):
    # RT template must start at the edit position
    rt_start = pos
    rt_end = pos + len(alt)

    rt = seq[rt_start:rt_end]

    # PBS is reverse complement of bases upstream of PAM
    pbs_source = seq[guide.start - 15 : guide.start]
    pbs = reverse_complement(pbs_source)

    return PrimeDesign(
        guide=guide,
        pbs=pbs,
        rt=alt + rt[len(ref):],
        edit_position=pos
    )

The real implementation handles strand direction, longer templates, indels, GC balancing, and mismatch flags, but the structure is similar.

Why this matters (and who uses it)

This tool is useful for:

CRISPR/Prime Editing researchers
Anyone designing therapeutics or knockouts
University labs
Biotech engineers needing quick sequence checks
Hobbyists learning genome engineering

Because it runs in the browser, there’s no install, no login, and no command-line wrangling.

And because everything is computed deterministically, users can paste sequences with confidence — the planner never silently adjusts anything.

What’s next

Off-target heuristic scanning
Genome-context lookup (hg38 / Ensembl)
Export lab notebook formats
Smarter prime editing scoring

Helix is growing fast, and this planner is just the beginning of a bigger ecosystem.

Happy editing and if you build anything with it, tell me. This project is becoming a surprisingly fun intersection of web engineering and genome design.

Veri-Helix: making bioinformatics reproducible, one figure at a time

Omnis Coder — Wed, 12 Nov 2025 16:17:25 +0000

The biology of the future will be built on proof.
Not just results that look right, but results that can prove where they came from.

Veri-Helix is an open-source Python toolkit that turns reproducibility into a first-class feature.
Every workflow, schema, and figure you generate carries cryptographic provenance and versioned validation — no more mystery plots or lost notebooks.

✳️ Why it matters

Most bioinformatics projects are a maze of scripts and notebooks.
A small tweak in data or dependencies can silently change your output.

Veri-Helix keeps you honest by stamping every artifact — from a FASTA triage plot to a motif logo — with:

✅ Schema validation (Pydantic-based) for every JSON artifact

🔖 Versioned spec manifests (spec_version = 1.0) so outputs stay compatible

🧾 Provenance metadata (tool version, timestamp, and input SHA-256) baked into each .viz.json and figure footer

If you can see it, you can verify it.

🧬 What’s inside

Unified CLI: one command (helix) for analysis, plotting, and schema inspection

Schema-verified visualization: RNA dot-plots, motif logos, distance heatmaps, alignment ribbons, and more

Validated workflows: YAML pipelines that log schema kind, version, and hash for every step

Reproducible demos: all screenshots on docs.verihelix.org come straight from helix demo viz

⚙️ Try it in a minute
pip install veri-helix[viz,schema,protein]
helix demo viz --all

Each command leaves a .viz.json next to your figure:

{
"kind": "motif_logo",
"spec_version": "1.0",
"input_sha256": "...",
"helix_version": "0.2.0",
"timestamp": "2025-11-11T18:23Z"
}

That JSON is your proof — a portable, machine-readable trail of how your science was made.

💡 Get started

Docs: https://omniscoder.github.io/Helix

PyPI: pypi.org/project/veri-helix

GitHub: github.com/omniscoder/Helix

🧠 For educators & researchers

Veri-Helix notebooks drop cleanly into Jupyter and Binder, letting students explore validated results without hidden state.
Every command can export a manifest that journals and repositories (like Zenodo) can archive alongside your paper.

🚀 Join us

Help shape the future of reproducible biology — contribute examples, workflows, or new schema definitions:

git clone https://github.com/omniscoder/Helix